Table 1 General characteristics of the patients
Variables | Total (n = 72) | Treatment (n = 36) | Control (n = 36) | |||
|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | |
Gender | ||||||
Male | 27 | (38) | 14 | (39) | 13 | (36) |
Female | 45 | (63) | 22 | (61) | 23 | (64) |
Age (years), Mean ± SD | 48.57 ± 14.80 | 49.42 ± 14.29 | 47.72 ± 15.45 | |||
<40 years | 18 | (25) | 10 | (28) | 8 | (22) |
40–65 years | 46 | (64) | 22 | (61) | 24 | (67) |
>65 years | 8 | (11) | 4 | (11) | 4 | (11) |
Underlying diseases | ||||||
Diabetes | 17 | (24) | 11 | (31) | 6 | (17) |
Hypertension | 29 | (40) | 16 | (44) | 13 | (36) |
Dyslipidemia | 25 | (35) | 16 | (44) | 9 | (25) |
Ischemic heart disease | 2 | (3) | 1 | (3) | 1 | (3) |
Peripheral arterial disease | 0 | (0) | 0 | (0) | 0 | (0) |
Malignancy | 0 | (0) | 0 | (0) | 0 | (0) |
HIV | 0 | (0) | 0 | (0) | 0 | (0) |
Cerebrovascular disease | 2 | (3) | 0 | (0) | 2 | (6) |
Alcoholism | 0 | (0) | 0 | (0) | 0 | (0) |
Chronic liver disease | 0 | (0) | 0 | (0) | 0 | (0) |
Chronic kidney disease stage | 5 | (7) | 2 | (6) | 3 | (8) |
Others | 29 | (40) | 13 | (36) | 16 | (44) |
Known mode of transmission | 26 | (36) | 15 | (42) | 11 | (31) |
COVID-19 vaccine | 48 | (67) | 23 | (64) | 25 | (69) |
1 dose | 34 | (47) | 18 | (50) | 16 | (44) |
2 dose | 13 | (18) | 5 | (14) | 8 | (22) |
Booster dose | 1 | (1) | 0 | (0) | 1 | (3) |
AstraZeneca | 41 | (57) | 20 | (56) | 21 | (58) |
Sinovac | 3 | (4) | 2 | (6) | 1 | (3) |
Sinopharm | 5 | (7) | 1 | (3) | 4 | (11) |
Time from last vaccine (days), median (IQR) | 57 | (34–66) | 59 | (38–70) | 44 | (11–64) |